ArticleAmerican journal of hematology2019
Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma.
Article in American journal of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 32 citations in OpenAlex.
- HAT-PCR is non-inferior to NGS when quantifying measurable residual disease for myeloma.British journal of haematology · 2026Article
- Next Generation Flow and Next Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma Patients: A Real-Life Italian Multicenter Harmonization Experience.Cancer medicine · 2026Article
- Characteristics of immunoglobulin gene rearrangements in vietnamese newly diagnosed multiple myeloma patients.Leukemia research reports · 2026Article
- Pomalidomide in patients with multiple myeloma: potential impact on the reconstitution of a functional T-cell immunity.Immunologic research · 2024Article
- Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence.Blood cancer journal · 2024Article
- Advances in estimating plasma cells in bone marrow: A comprehensive method review.African journal of laboratory medicine · 2024Review
- Review
- Article
- Complete variable domain sequences of monoclonal antibody light chains identified from untargeted RNA sequencing data.Frontiers in immunology · 2023Article
- Single-Cell RNA Sequencing for the Detection of Clonotypic V(D)J Rearrangements in Multiple Myeloma.International journal of molecular sciences · 2022Article
- Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside.Experimental hematology & oncology · 2022Review
- Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Monitoring multiple myeloma in the peripheral blood based on cell-free DNA and circulating plasma cells.Annals of hematology · 2022Article
- Single-cell RNA-seq reveals clonal diversity and prognostic genes of relapsed multiple myeloma.Clinical and translational medicine · 2022Article
- Circulating T-Cell Repertoires Correlate With the Tumor Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy.JCO precision oncology · 2022Article
- Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.Blood reviews · 2021Review
- Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications.Frontiers in oncology · 2021Review
- Isabl Platform, a digital biobank for processing multimodal patient data.BMC bioinformatics · 2020Article
- Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma.Blood advances · 2020Article
- Timing the initiation of multiple myeloma.Nature communications · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 7 institutions in 3 countries.
Funding
Abstract
Minimal residual disease (MRD) tracking, by next generation sequencing of immunoglobulin sequences, is moving towards clinical implementation in multiple myeloma. However, there is only sparse information available to address whether clonal sequences remain stable for tracking over time, and to what extent light chain sequences are sufficiently unique for tracking. Here, we analyzed immunoglobulin repertoires from 905 plasma cell myeloma and healthy control samples, focusing on the third complementarity determining region (CDR3). Clonal heavy and/or light chain expression was identified in all patients at baseline, with one or more subclones related to the main clone in 3.2%. In 45 patients with 101 sequential samples, the dominant clonal CDR3 sequences remained identical over time, despite differential clonal evolution by whole exome sequencing in 49% of patients. The low frequency of subclonal CDR3 variants, and absence of evolution over time in active multiple myeloma, indicates that tumor cells at this stage are not under selective pressure to undergo antibody affinity maturation. Next, we establish somatic hypermutation and non-templated insertions as the most important determinants of light chain clonal uniqueness, identifying a potentially trackable sequence in the majority of patients. Taken together, we show that dominant clonal sequences identified at baseline are reliable biomarkers for long-term tracking of the malignant clone, including both IGH and the majority of light chain clones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.